Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "James H. Doroshow" Clear advanced filters

  • The launch of phase '0' trials has generated much discussion in the cancer research community. This Perspective, written by scientists at the US National Cancer Institute, discusses the aims of these trials, gives some practical advice for conducting them and addresses several outstanding questions.

    • Shivaani Kummar
    • Robert Kinders
    • James H. Doroshow
    Reviews
    Nature Reviews Cancer
    Volume: 7, P: 131-139

  • Developing optimal combination strategies for molecularly targeted anticancer drugs is substantially more complex than for traditional chemotherapies. Here, Doroshow and colleagues discuss the lessons learned from the evaluation of combinations of molecularly targeted anticancer agents by the US National Cancer Institute (NCI), and highlight several new approaches that the NCI has initiated to improve the effectiveness of such combinations.

    • Shivanni Kummar
    • Helen X. Chen
    • James H. Doroshow
    Reviews
    Nature Reviews Drug Discovery
    Volume: 9, P: 843-856

  • Combination strategies of molecular-targeted agents (MTAs) are being used in the hope of optimizing antitumour efficacy and to minimize the development of resistance, but very little effort is focused on molecular vulnerabilities of normal tissues. This Review discusses the main toxicities and the lack of tolerability of some common MTA combinations, and highlights what steps can be introduced for new preclinical testing paradigms for the assessment of chronic toxicities.

    • Sook Ryun Park
    • Myrtle Davis
    • Shivaani Kummar
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 10, P: 154-168

  • The landscape of translational oncology has shifted dramatically over the past 10 years, characterized by the introduction of more-sophisticated molecular tools into the clinic and advances are being employed in genomic clinical trials that will examine the feasibility of matching a broad range of systemic therapies to specific molecular tumour characteristics. The authors review selected developments in translational cancer biology, diagnostics, and therapeutics that have occurred over the past decade and offer our thoughts on future prospects for the next few years.

    • James H. Doroshow
    • Shivaani Kummar
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 11, P: 649-662